AVROBIO Inc (NASDAQ:AVRO)

0.6557
BATS BZX Real-Time Price
As of Sep 29
 0.00 / 0.00%
Today’s Change
0.64
Today|||52-Week Range
6.62
-82.97%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$47.7M

Company Description

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.

Contact Information

Avrobio, Inc.
100 Technology Square
Cambridge Massachusetts 02139
P:(617) 914-8420
Investor Relations:

Employees

Shareholders

Other institutional38.67%
Individual stakeholders30.91%
Mutual fund holders11.01%

Top Executives

Geoff MacKayPresident, Chief Executive Officer & Director
Erik John OstrowskiChief Financial Officer & Treasurer
Kim RaineriChief Manufacturing & Technical Operations Officer
Essra RidhaChief Medical Officer
Deanna M. PetersenChief Business Officer